Clinical Trial Detail

NCT ID NCT02329847
Title Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

CLL/SLL

non-Hodgkin lymphoma

Therapies

Ibrutinib + Nivolumab

Age Groups: adult

No variant requirements are available.